FAT1 and colorectal cancer: To improve the targeted treatment of colorectal cancer by mAb198.3 (a FAT1-specific monoclonal antibody), Grifantini et al. [103] developed two different novel drug delivery systems having magnetic properties to improve the targeted treatment of colorectal cancer by mAb198.3 (a FAT1-specific monoclonal antibody), where mAb198.3 was directly bound to super-paramagnetic nanoparticles or embedded into human erythrocyte-based magnetized carriers.